Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 177

1.

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.

Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA.

J Pathol. 2012 Jan;226(1):7-16. doi: 10.1002/path.2995. Epub 2011 Nov 10.

PMID:
22072542
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.

Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C.

Acta Neuropathol. 2012 Jun;123(6):853-60. doi: 10.1007/s00401-012-0993-5. Epub 2012 May 17.

PMID:
22588899
[PubMed - indexed for MEDLINE]
3.

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.

PMID:
23681562
[PubMed - indexed for MEDLINE]
4.
5.

Oligodendrogliomas: new insights from the genetics and perspectives.

Alentorn A, Sanson M, Idbaih A.

Curr Opin Oncol. 2012 Nov;24(6):687-93. doi: 10.1097/CCO.0b013e328357f4ea. Review.

PMID:
22913971
[PubMed - indexed for MEDLINE]
6.

1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.

Neuro Oncol. 2013 Jun;15(6):775-82. doi: 10.1093/neuonc/not027. Epub 2013 Mar 13.

PMID:
23486687
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

PMID:
22136423
[PubMed - indexed for MEDLINE]
8.

Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.

Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A.

J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22.

PMID:
15099021
[PubMed - indexed for MEDLINE]
9.

Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.

Kanamori M, Kumabe T, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Suzuki H, Watanabe M, Tominaga T.

Brain Tumor Pathol. 2013 Jul;30(3):151-9. doi: 10.1007/s10014-012-0119-8. Epub 2012 Oct 2.

PMID:
23053495
[PubMed - indexed for MEDLINE]
10.

Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.

Mur P, Mollejo M, Ruano Y, de Lope ÁR, Fiaño C, García JF, Castresana JS, Hernández-Laín A, Rey JA, Meléndez B.

Acta Neuropathol. 2013 Aug;126(2):277-89. doi: 10.1007/s00401-013-1130-9. Epub 2013 May 21.

PMID:
23689617
[PubMed - indexed for MEDLINE]
11.

Novel CIC point mutations and an exon-spanning, homozygous deletion identified in oligodendroglial tumors by a comprehensive genomic approach including transcriptome sequencing.

Eisenreich S, Abou-El-Ardat K, Szafranski K, Campos Valenzuela JA, Rump A, Nigro JM, Bjerkvig R, Gerlach EM, Hackmann K, Schröck E, Krex D, Kaderali L, Schackert G, Platzer M, Klink B.

PLoS One. 2013 Sep 27;8(9):e76623. doi: 10.1371/journal.pone.0076623. eCollection 2013.

PMID:
24086756
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.

Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH.

Neuropathology. 2007 Feb;27(1):10-20.

PMID:
17319279
[PubMed - indexed for MEDLINE]
13.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

PMID:
20160062
[PubMed - indexed for MEDLINE]
Free Article
14.

Mutations in CIC and FUBP1 contribute to human oligodendroglioma.

Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SK, Vogelstein B, Bigner D, Yan H, Papadopoulos N, Kinzler KW.

Science. 2011 Sep 9;333(6048):1453-5. doi: 10.1126/science.1210557. Epub 2011 Aug 4.

PMID:
21817013
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.

Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T.

Clin Cancer Res. 2002 Jan;8(1):196-201.

PMID:
11801559
[PubMed - indexed for MEDLINE]
Free Article
16.

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP.

Neuro Oncol. 2009 Aug;11(4):341-7. doi: 10.1215/15228517-2009-025. Epub 2009 May 12.

PMID:
19435942
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.

Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.

Acta Neuropathol. 2002 Mar;103(3):267-75. Epub 2001 Nov 22.

PMID:
11907807
[PubMed - indexed for MEDLINE]
18.

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.

Chin Med J (Engl). 2010 Dec;123(24):3566-73.

PMID:
22166632
[PubMed - indexed for MEDLINE]
Free Article
19.

Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.

Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M.

Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71.

PMID:
14507338
[PubMed - indexed for MEDLINE]
20.

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.

J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9.

PMID:
9776413
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk